Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10218399" target="_blank" >RIV/00216208:11110/14:10218399 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10218399

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00415-013-7196-4" target="_blank" >http://dx.doi.org/10.1007/s00415-013-7196-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00415-013-7196-4" target="_blank" >10.1007/s00415-013-7196-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Popis výsledku v původním jazyce

Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effectsof daclizumab high-yield process (DAC HYP) vs. placebo in patients with highly active RRMS in the SELECT study. Highly active RRMS was defined as patients with a parts per thousand yen2 relapses in the year before randomization and a parts per thousand yen1 gadolinium-enhancing (Gd+) lesion at baseline. Because results were similar in the DAC HYP dose groups, data from the DAC HYP arms were pooled for analysis. Treatment with DAC HYP resulted in similar effects in highly active (n = 88) and less active(n = 506) RRMS patients. DAC HYP reduced the annualized relapse rate by 50 % and 51 % in the highly active (p = 0.0394) and less active (p < 0.0001) groups vs. placebo, respectively (interaction p = 0.82). DAC HYP reduced new/newly-enlarg

Název v anglickém jazyce

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Popis výsledku anglicky

Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effectsof daclizumab high-yield process (DAC HYP) vs. placebo in patients with highly active RRMS in the SELECT study. Highly active RRMS was defined as patients with a parts per thousand yen2 relapses in the year before randomization and a parts per thousand yen1 gadolinium-enhancing (Gd+) lesion at baseline. Because results were similar in the DAC HYP dose groups, data from the DAC HYP arms were pooled for analysis. Treatment with DAC HYP resulted in similar effects in highly active (n = 88) and less active(n = 506) RRMS patients. DAC HYP reduced the annualized relapse rate by 50 % and 51 % in the highly active (p = 0.0394) and less active (p < 0.0001) groups vs. placebo, respectively (interaction p = 0.82). DAC HYP reduced new/newly-enlarg

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neurology

ISSN

0340-5354

e-ISSN

—

Svazek periodika

261

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

316-323

Kód UT WoS článku

000330963200009

EID výsledku v databázi Scopus

—